Symtuza
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Symtuza ([darunavir + cobicistat + emtricitabine + tenofovir alafenamide (TAF)]; Johnson & Johnson) is a once-daily single-tablet regimen (STR) combination of the protease inhibitor (PI) Prezista, the two nucleos(t)ide reverse transcriptase inhibitors (NRTIs), Emtriva (emtricitabine; Gilead) and TAF (Gilead), and the boosting agent Tybost (cobicistat; Gilead). Symtuza is the first STR containing a PI.
While its convenience as a STR and the high resistance barrier of darunavir position Symtuza as a good alternative for treatment-experienced patients who have generated resistance to other regimens, it will struggle to compete in the first-line setting due to its late launch, generic threats, and fierce competition from Triumeq ([dolutegravir + abacavir + lamivudine]; ViiV Healthcare) and Biktarvy ([bictegravir + emtricitabine + TAF]; Gilead).
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Symtuza : HIV
LIST OF FIGURES
10 Figure 29: Datamonitor Healthcare’s drug assessment summary of Ofev for idiopathic pulmonary fibrosis
11 Figure 30: Datamonitor Healthcare’s drug assessment summary of Ofev for idiopathic pulmonary fibrosis
14 Figure 31: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
LIST OF TABLES
6 Table 1: Symtuza drug profile
6 Table 2: Approval history of Symtuza for HIV in the US and five major EU markets
8 Table 3: Late-phase trials of Symtuza for HIV
9 Table 4: Symtuza for HIV – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Odefsey 
Sign up to the